TP53 and seminoma: In a recent multi-institutional study focused on PMGCTs, TP53 genomic alterations were described in 56% of non-seminoma tumors and were associated with significantly shorter OS than in patients with wild-type TP53 PMGCTs, suggesting a distinct genomic background in patients with PMGCTs which could explain the poor prognosis of this patient population [32].